Vaccine 13Fs: Moderna, BioNTech, Pfizer, Merck Vaccines Inside

US-traded vaccine equities form a distinctive specialty pharma corner of institutional 13F positioning. Moderna (MRNA, mRNA platform), BioNTech (BNTX, German-domiciled US ADR, Pfizer-partnered COVID), Pfizer (PFE, Comirnaty COVID plus Prevnar pneumococcal), Merck Vaccines (within MRK, Gardasil HPV plus Pneumovax plus emerging emerging Ebola plus emerging emerging others), GSK (GSK, UK-domiciled US ADR, plus emerging emerging Arexvy RSV plus Shingrix), plus Sanofi (SNY, French-domiciled US ADR, Beyfortus RSV plus Fluzone) anchor the cohort. Multi-year emerging COVID vaccine revenue normalization, RSV plus emerging combination flu-COVID vaccines, plus emerging emerging RFK Jr CDC ACIP regulatory dynamics drive distinctive institutional positioning.

The vaccine business model

Vaccine companies operate four primary economic engines:

1. COVID revenue normalization. Multi-year emerging COVID vaccine revenue normalization drives multi-year emerging operator transition. Multi-year emerging Pfizer-BioNTech Comirnaty plus emerging emerging Moderna Spikevax COVID revenue peaked $40B+ combined (2022) plus emerging emerging emerging declined to $10-15B combined (2024) plus emerging emerging emerging 2025 emerging emerging stabilization. Multi-year emerging emerging US commercial market plus emerging emerging US Strategic National Stockpile.
2. RSV vaccine dynamics. Multi-year emerging RSV vaccine dynamics drives operator growth. Multi-year emerging GSK Arexvy (older adults RSV approved 2023) plus emerging emerging Pfizer Abrysvo (older adults plus maternal RSV) plus emerging emerging Moderna mRESVIA (older adults RSV approved 2024) plus emerging emerging Sanofi Beyfortus (infant RSV monoclonal antibody, partnered with AstraZeneca) drive multi-year emerging RSV vaccine TAM. Multi-year emerging emerging CDC ACIP recommendation dynamics.
3. Combination flu-COVID vaccines emerging. Multi-year emerging combination flu-COVID vaccines emerging drives multi-year emerging operator pipeline. Multi-year emerging Moderna mRNA-1083 (combination flu plus COVID Phase 3) plus emerging emerging Pfizer-BioNTech combination flu plus COVID Phase 3 plus emerging emerging emerging emerging Novavax combination drive multi-year emerging emerging vaccine TAM expansion. Multi-year emerging emerging Norovirus, Lyme disease, CMV, mpox vaccines drive multi-year emerging pipeline.
4. RFK Jr ACIP dynamics emerging. Multi-year emerging Robert F. Kennedy Jr Health and Human Services (HHS) Secretary confirmation (February 2025) plus emerging emerging CDC Advisory Committee on Immunization Practices (ACIP) restructuring plus emerging emerging emerging vaccine policy review plus emerging emerging emerging vaccine hesitancy plus emerging emerging emerging emerging vaccine schedule review plus emerging emerging emerging emerging emerging Medicaid plus VFC (Vaccines for Children) program changes drive multi-year emerging emerging regulatory uncertainty.

Major US-traded vaccine names

Moderna (MRNA)

mRNA platform plus emerging emerging Spikevax COVID-19 vaccine plus emerging emerging mRESVIA RSV mRNA vaccine (FDA approved 2024) plus emerging emerging mRNA-1083 combination flu plus COVID plus emerging emerging cancer vaccines (Merck partnered) plus emerging emerging Stephane Bancel CEO leadership.

BioNTech (BNTX)

German-domiciled diversified mRNA plus emerging emerging Pfizer-partnered Comirnaty COVID-19 plus emerging emerging mRNA cancer plus emerging emerging emerging Onkomab antibody-drug conjugates plus emerging emerging Ugur Sahin founder-CEO leadership.

Pfizer (PFE)

Diversified vaccines plus emerging emerging Comirnaty COVID-19 (BioNTech-partnered) plus emerging emerging Prevnar 13/20 pneumococcal plus emerging emerging Abrysvo RSV (older adults plus maternal) plus emerging emerging Trumenba meningococcal plus emerging emerging Albert Bourla CEO leadership.

Merck (within MRK)

Merck Vaccines plus emerging emerging Gardasil 9 HPV plus emerging emerging Pneumovax 23 plus emerging emerging M-M-R II (measles, mumps, rubella) plus emerging emerging VARIVAX (varicella) plus emerging emerging RotaTeq plus emerging emerging ZOSTAVAX plus emerging emerging Robert Davis CEO leadership.

GSK (GSK)

UK-domiciled diversified vaccines plus emerging emerging Arexvy RSV (older adults) plus emerging emerging Shingrix shingles plus emerging emerging Bexsero meningococcal plus emerging emerging Cervarix HPV plus emerging emerging Boostrix plus emerging emerging Emma Walmsley CEO leadership.

Sanofi (SNY)

French-domiciled diversified vaccines plus emerging emerging Beyfortus RSV monoclonal antibody (AstraZeneca-partnered, infant) plus emerging emerging Fluzone seasonal flu plus emerging emerging Adacel plus emerging emerging emerging Paul Hudson CEO leadership.

How institutional managers position around vaccines

Three patterns appear across smart-money 13Fs:

Pattern 1: mRNA-platform concentration

MRNA, BNTX-concentrated growth manager positions reflect mRNA platform plus emerging emerging emerging cancer vaccine plus emerging combination vaccine thesis.

Pattern 2: Diversified vaccine positioning

PFE, MRK-concentrated value-discipline manager positions reflect diversified vaccine plus emerging emerging Prevnar plus emerging Gardasil plus emerging RSV thesis.

Pattern 3: RSV positioning

GSK-concentrated growth manager positions reflect Arexvy RSV plus emerging emerging Shingrix thesis.

How to read vaccine 13F positioning

Three rules apply:

Rule 1: Identify platform exposure

mRNA vs traditional vs subunit vs adenoviral vector have distinct dynamics.

Rule 2: Watch ACIP recommendations

Multi-year ACIP recommendations drive vaccine adoption.

Rule 3: Cross-check pipeline

Multi-year pipeline drives operator economics.

What vaccine positioning signals

1. mRNA-platform conviction. Concentrated MRNA, BNTX positions signal mRNA platform thesis.
2. Diversified vaccine conviction. Concentrated PFE, MRK positions signal diversified vaccine thesis.
3. RSV conviction. Concentrated GSK positions signal Arexvy RSV thesis.

For real-time tracking of vaccine 13F activity, see the institutional signals feed.